di Reumatologia, S.I. (tran.) (2026) “PO:35:218 | Switching the dose of mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European retrospective multicentre real-world study: Edoardo Biancalana1, Irene Mattioli1, Emanuele Chiara2, Danilo Malandrino1, Maria Canfora1, Palmerini Miki1, Maria Paola Lisi1, Michela Gasparotto3, Paola Tomietto3, Maria Letizia Urban1, Giacomo Bagni1, Elena Silvestri1, Alessandra Bettiol3, Augusto Vaglio3, Giacomo Emmi2 | 1Department of Experimental and Clinical Medicine, University of Florence Firenze, Italy; 2Department of Medical, Surgery and Health Sciences, University of Trieste Trieste, Italy; 3Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Trieste, Italy; 4Department of Biomedical, Experimental and Clinical Sciences Mario Serio, University of Florence Firenze, Italy”, Reumatismo, 77(s1). doi:10.4081/reumatismo.2025.2381.